UNSPSC 51263129: Oxprenolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 519MXN9YZR, chemically known as 2-propanol, 1-(2-allyloxyphenoxy)-3-(isopropylamino)- but generally known as oxprenolol, which bears US NIH Compound Identifier 4631. European Medicines Agency schedules Oxprenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09555MIG.

UNSPSC 51263129 Oxprenolol is a Commodity code that in practice encompasses pharmaceutical products and drug-related systems procured by state and local health agencies, though the recent opportunities block shows minimal activity directly aligned with the code's nominal scope. The two identified state and local solicitations — Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs — target broader pharmaceutical procurement and opioid-response initiatives rather than oxprenolol specifically. Issuing bodies under this code include county health departments and state HHS agencies; Seminole County and Texas HHS are the only repeat buyers in the recent record.

Activity appears concentrated in the Southeast and South, with Seminole County, Florida and Texas HHS representing the two most recent postings. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida; the bid deadline was July 26, 2023 (note: a discrepancy in the source date). Texas HHS posted RFI HHS0017013 on April 3, 2026, requesting vendor capability information on direct-to-manufacturer prescription programs as a preliminary market-intelligence step prior to formal solicitation. The code shows limited recent activity with direct relevance to oxprenolol procurement — the opportunities posted are broader pharmaceutical and opioid-response initiatives, signaling either infrequent standalone demand for this specific beta-blocker or potential misclassification in state and local tagging practice.